Safety Update on Dapagliflozin (DAPA) across the Phase 2b/3 Clinical Trial Program

被引：0
|
作者：
Jabbour, Serge A.
Seufert, Jochen
Scheen, Andre J.
Bailey, Clifford J.
Karup, Cathrina
Langkilde, Anna Maria
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1263-P
引用
收藏
页码：A338 / A339
页数：2
相关论文
共 50 条
  • [1] Safety update on dapagliflozin across the phase 2b/3 clinical trial programme
    Scheen, A. J. L.
    Jabbour, S.
    Seufert, J.
    Bailey, C. J.
    Karup, C.
    Langkilde, A. M.
    DIABETOLOGIA, 2017, 60 : S419 - S419
  • [2] Safety update: Risdiplam clinical trial development program
    Chiriboga, C.
    Servais, L.
    Baranello, G.
    Darras, B.
    Day, J.
    Deconinck, N.
    Farrar, M.
    Finkel, R.
    Bertini, E.
    Kirschner, J.
    Masson, R.
    Mazurkiewicz-Beldzinska, M.
    Vlodavets, D.
    Bader-Weder, S.
    Gorni, K.
    Jaber, B.
    McIver, T.
    Papp, G.
    Scalco, R.
    Mercuri, E.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S89 - S89
  • [3] Positive Phase 2b Clinical Trial of Psoriasis Drug Apremilast
    不详
    JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (03) : 283 - 283
  • [4] Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease A Truncated Randomized Phase 2b/3 Clinical Trial
    Sperling, Reisa
    Henley, David
    Aisen, Paul S.
    Raman, Rema
    Donohue, Michael C.
    Ernstrom, Karin
    Rafii, Michael S.
    Streffer, Johannes
    Shi, Yingqi
    Karcher, Keith
    Raghavan, Nandini
    Tymofyeyev, Yevgen
    Bogert, Jennifer
    Brashear, H. Robert
    Novak, Gerald
    Thipphawong, John
    Saad, Ziad S.
    Kolb, Hartmuth
    Rofael, Hany
    Sanga, Panna
    Romano, Gary
    JAMA NEUROLOGY, 2021, 78 (03) : 293 - 301
  • [5] Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
    Heerspink, Hiddo J. L.
    Kiyosue, Arihiro
    Wheeler, David C.
    Lin, Min
    Wijkmark, Emma
    Carlson, Glenn
    Mercier, Anne-Kristina
    Astrand, Magnus
    Ueckert, Sebastian
    Greasley, Peter J.
    Ambery, Phil
    LANCET, 2023, 402 (10416): : 2004 - 2017
  • [6] Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
    Ezzedine, Khaled
    Peeva, Elena
    Yamaguchi, Yuji
    Cox, Lori Ann
    Banerjee, Anindita
    Han, George
    Hamzavi, Iltefat
    Ganesan, Anand K.
    Picardo, Mauro
    Thaci, Diamant
    Harris, John E.
    Bae, Jung Min
    Tsukamoto, Katsuhiko
    Sinclair, Rodney
    Pandya, Amit G.
    Sloan, Abigail
    Yu, Dahong
    Gandhi, Kavita
    Vincent, Michael S.
    King, Brett
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (02) : 395 - 403
  • [7] COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Study Design and Trial Update
    Oskarsson, Bjorn
    Dojillo, Joanna
    Makhay, Malath
    Matsuda, Kazuko
    NEUROLOGY, 2020, 94 (15)
  • [8] Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
    Dodick, David W.
    Lipton, Richard B.
    Silberstein, Stephen
    Goadsby, Peter J.
    Biondi, David
    Hirman, Joe
    Cady, Roger
    Smith, Jeff
    CEPHALALGIA, 2019, 39 (09) : 1075 - 1085
  • [9] Safety and tolerability of opicinumab in relapsing multiple sclerosis: the Phase 2b SYNERGY trial
    Freeman, S.
    Selmaj, K.
    Fernandez, O.
    Grimaldi, L.
    Silber, E.
    Pardo, G.
    Freedman, S. M.
    Zhang, Y.
    Xu, L.
    Mellion, M.
    Cadavid, D.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 323 - 324
  • [10] Safety and Tolerability of Opicinumab in Relapsing Multiple Sclerosis: the Phase 2b SYNERGY Trial
    McCroskery, Peter
    Selmaj, Krzysztof
    Fernandez, Oscar
    Grimaldi, Luigi M. E.
    Silber, Eli
    Pardo, Gabriel
    Freedman, S. Mitchell
    Zhang, Yiwei
    Xu, Lei
    Cadavid, Diego
    Mellion, Michelle
    NEUROLOGY, 2017, 88
12345